

**ANNEE 2016**

N°

# **Traitement des angiomyolipomes rénaux par embolisation artérielle sélective: une étude rétrospective de 23 cas.**

**THESE**

présentée

à l'UFR des Sciences de Santé de Dijon  
Circonscription Médecine  
et soutenue publiquement le 6 octobre 2016  
pour obtenir le grade de Docteur en Médecine

par **BARDIN Florian**

Né le 01/08/1985

à Dijon (21)



**ANNEE 2016**

N°

# **Traitement des angiomyolipomes rénaux par embolisation artérielle sélective: une étude rétrospective de 23 cas.**

**THESE**

présentée

à l'UFR des Sciences de Santé de Dijon  
Circonscription Médecine  
et soutenue publiquement le 6 octobre 2016  
pour obtenir le grade de Docteur en Médecine

par **BARDIN Florian**

Né le 01/08/1985

à Dijon (21)

Année Universitaire 2016-2017  
au 1<sup>er</sup> Septembre 2016

**Doyen :**

1<sup>er</sup> Assesseur :

Assesseurs :

**M. Frédéric HUET**

M. Yves ARTUR

Mme Laurence DUVILLARD

M. Pablo ORTEGA-DEBALLON

M. Marc MAYNADIE

## PROFESSEURS DES UNIVERSITES - PRATICIENS HOSPITALIERS

			<b>Discipline</b>
M.	Marc	<b>BARDOU</b>	Pharmacologie clinique
M.	Jean-Noël	<b>BASTIE</b>	Hématologie - transfusion
M.	Emmanuel	<b>BAULOT</b>	Chirurgie orthopédique et traumatologie
M.	Laurent	<b>BEDENNE</b>	Gastroentérologie et hépatologie
M.	Yannick	<b>BEJOT</b>	Neurologie
M.	Alain	<b>BERNARD</b>	Chirurgie thoracique et cardiovasculaire
M.	Jean-François	<b>BESANCENOT</b>	Médecine interne
Mme	Christine	<b>BINQUET</b>	Epidémiologie, économie de la santé et prévention
M.	Bernard	<b>BONIN</b>	Psychiatrie d'adultes
M.	Philippe	<b>BONNIAUD</b>	Pneumologie
M.	Alain	<b>BONNIN</b>	Parasitologie et mycologie
M.	Bernard	<b>BONNOTTE</b>	Immunologie
M.	Olivier	<b>BOUCHOT</b>	Chirurgie cardiovasculaire et thoracique
M.	Belaïd	<b>BOUHEMAD</b>	Anesthésiologie - réanimation chirurgicale
M.	Alexis	<b>BOZORG-GRAYELI</b>	ORL
M.	Alain	<b>BRON</b>	Ophthalmologie
M.	Laurent	<b>BRONDEL</b>	Physiologie
M.	François	<b>BRUNOTTE</b>	Biophysique et Médecine Nucléaire
M.	Patrick	<b>CALLIER</b>	Génétique
M.	Jean-Marie	<b>CASILLAS-GIL</b>	Médecine physique et réadaptation
Mme	Catherine	<b>CHAMARD-NEUWIRTH</b>	Bactériologie - virologie; hygiène hospitalière
M.	Pierre-Emmanuel	<b>CHARLES</b>	Réanimation
M.	Pascal	<b>CHAVANET</b>	Maladies infectieuses
M.	Nicolas	<b>CHEYNEL</b>	Anatomie
M.	Alexandre	<b>COCHET</b>	Biophysique et médecine nucléaire
M.	Luc	<b>CORMIER</b>	Urologie
M.	Yves	<b>COTTIN</b>	Cardiologie
M.	Charles	<b>COUTANT</b>	Gynécologie-obstétrique
M.	Gilles	<b>CREHANGE</b>	Oncologie-radiothérapie
Mme	Catherine	<b>CREUZOT-GARCHER</b>	Ophthalmologie
M.	Frédéric	<b>DALLE</b>	Parasitologie et mycologie
M.	Serge	<b>DOUVIER</b>	Gynécologie-obstétrique
Mme	Laurence	<b>DUVILLARD</b>	Biochimie et biologie moléculaire
Mme	Laurence	<b>FAIVRE-OLIVIER</b>	Génétique médicale
Mme	Patricia	<b>FAUQUE</b>	Biologie et Médecine du Développement
Mme	Irène	<b>FRANCOIS-PURSELL</b>	Médecine légale et droit de la santé
M.	Pierre	<b>FUMOLEAU</b>	Cancérologie
M.	François	<b>GHIRINGHELLI</b>	Cancérologie
M.	Claude	<b>GIRARD</b>	Anesthésiologie – réanimation chirurgicale
M.	Vincent	<b>GREMEAUX</b>	Médecine physique et réadaptation
M.	Frédéric	<b>HUET</b>	Pédiatrie
M.	Pierre	<b>JOUANNY</b>	Gériatrie

M.	Denis	<b>KRAUSÉ</b>	Radiologie et imagerie médicale
M.	Sylvain	<b>LADOIRE</b>	Histologie
M.	Gabriel	<b>LAURENT</b>	Cardiologie
M.	Côme	<b>LEPAGE</b>	Hépatogastroentérologie
M.	Romarc	<b>LOFFROY</b>	Radiologie et imagerie médicale
M.	Luc	<b>LORGIS</b>	Cardiologie
M.	Jean-François	<b>MAILLEFERT</b>	Rhumatologie
M.	Cyriaque Patrick	<b>MANCKOUNDIA</b>	Gériatrie
M.	Sylvain	<b>MANFREDI</b>	Hépatogastroentérologie
M.	Laurent	<b>MARTIN</b>	Anatomie et cytologie pathologiques
M.	David	<b>MASSON</b>	Biochimie et biologie moléculaire
M.	Marc	<b>MAYNADIE</b>	Hématologie - transfusion
M.	Thibault	<b>MOREAU</b>	Neurologie
M.	Klaus Luc	<b>MOURIER</b>	Neurochirurgie
Mme	Christiane	<b>MOUSSON</b>	Néphrologie
M.	Paul	<b>ORNETTI</b>	Rhumatologie
M.	Pablo	<b>ORTEGA-DEBALLON</b>	Chirurgie Générale
M.	Jean-Michel	<b>PETIT</b>	Endocrinologie, diabète et maladies métaboliques
M.	Lionel	<b>PIROTH</b>	Maladies infectieuses
Mme	Catherine	<b>QUANTIN</b>	Biostatistiques, informatique médicale
M.	Jean-Pierre	<b>QUENOT</b>	Réanimation
M.	Patrick	<b>RAT</b>	Chirurgie générale
M.	Jean-Michel	<b>REBIBOU</b>	Néphrologie
M.	Frédéric	<b>RICOLFI</b>	Radiologie et imagerie médicale
M.	Paul	<b>SAGOT</b>	Gynécologie-obstétrique
M.	Emmanuel	<b>SAPIN</b>	Chirurgie Infantile
M.	Henri-Jacques	<b>SMOLIK</b>	Médecine et santé au travail
M.	Éric	<b>STEINMETZ</b>	Chirurgie vasculaire
Mme	Christel	<b>THAUVIN</b>	Génétique
M.	Pierre	<b>VABRES</b>	Dermato-vénéréologie
M.	Bruno	<b>VERGÈS</b>	Endocrinologie, diabète et maladies métaboliques
M.	Narcisse	<b>ZWETYENGA</b>	Chirurgie maxillo-faciale et stomatologie

## PROFESSEURS ASSOCIES DES DISCIPLINES MEDICALES

M.	Bruno	<b>MANGOLA</b>	Urgences (du 01/05/2016 au 14/11/2016)
----	-------	----------------	--

## PROFESSEURS EN SURNOMBRE

M.	Roger	<b>BRENOT</b>	(surnombre jusqu'au 31/08/2018)
M.	Philippe	<b>CAMUS</b>	(surnombre jusqu'au 31/08/2019)
Mme	Monique	<b>DUMAS-MARION</b>	(surnombre jusqu'au 31/08/2018)
M.	Maurice	<b>GIROUD</b>	(surnombre jusqu'au 21/08/2018)
M.	Frédéric	<b>MICHEL</b>	(surnombre du 20/10/2015 au 31/12/2016)
M.	Pierre	<b>TROUILLOUD</b>	(surnombre du 05/02/2014 au 31/08/2017)

**MAITRES DE CONFERENCES DES UNIVERSITES  
PRATICIENS HOSPITALIERS DES DISCIPLINES MEDICALES**

			<b>Discipline Universitaire</b>
M.	Sylvain	<b>AUDIA</b>	Médecine interne
Mme	Shaliha	<b>BECHOUA</b>	Biologie et médecine du développement
Mme	Marie-Claude	<b>BRINDISI</b>	Nutrition
M.	Jean-Christophe	<b>CHAUVET-GELINIER</b>	Psychiatrie, psychologie médicale
(Mobilité Novembre 2016 à 2017)			
M.	Alexis	<b>DE ROUGEMONT</b>	Bactériologie-virologie ; hygiène hospitalière
M.	Hervé	<b>DEVILLIERS</b>	Médecine interne
M.	Olivier	<b>FACY</b>	Chirurgie générale
Mme	Ségoène	<b>GAMBERT-NICOT</b>	Biochimie et biologie moléculaire
Mme	Françoise	<b>GOIRAND</b>	Pharmacologie fondamentale
Mme	Agnès	<b>JACQUIN</b>	Physiologie
M.	Alain	<b>LALANDE</b>	Biophysique et médecine nucléaire
M.	Louis	<b>LEGRAND</b>	Biostatistiques, informatique médicale
Mme	Stéphanie	<b>LEMAIRE-EWING</b>	Biochimie et biologie moléculaire
M	Maxime	<b>SAMSON</b>	Médecine interne
(Mobilité Novembre 2016 à 2017)			
M.	Benoit	<b>TROJAK</b>	Psychiatrie d'adultes ; addictologie
M.	Paul-Mickaël	<b>WALKER</b>	Biophysique et médecine nucléaire

**PROFESSEURS EMERITES**

M.	Jean	<b>CUISENIER</b>	(01/09/2014 au 31/08/2017)
M.	Jean	<b>FAIVRE</b>	(01/09/2012 au 31/08/2018)
M.	Marc	<b>FREYSZ</b>	(01/09/2016 au 28/02/2017)
M	Philippe	<b>GAMBERT</b>	(01/09/2014 au 31/08/2017)
M.	Patrick	<b>HILLON</b>	(01/09/2016 au 31/08/2019)
M.	François	<b>MARTIN</b>	(01/09/2015 au 31/08/2018)
M.	Pierre	<b>POTHIER</b>	(01/09/2015 au 31/08/2018)

**PROFESSEURS DES UNIVERSITES DE MEDECINE GENERALE**

M.	Jean-Noël	<b>BEIS</b>	Médecine Générale
----	-----------	-------------	-------------------

**PROFESSEURS ASSOCIES DE MEDECINE GENERALE**

M.	Didier	<b>CANNET</b>	Médecine Générale
M.	Gilles	<b>MOREL</b>	Médecine Générale
M.	François	<b>MORLON</b>	Médecine Générale

**MAITRES DE CONFERENCES ASSOCIES DE MEDECINE GENERALE**

M.	Clément	<b>CHARRA</b>	Médecine Générale
M.	Rémi	<b>DURAND</b>	Médecine Générale
M.	Arnaud	<b>GOUGET</b>	Médecine Générale
Mme	Anne	<b>WALDNER-COMBERNOUX</b>	Médecine Générale

### **MAITRES DE CONFERENCES DES UNIVERSITES**

M.	Didier	<b>CARNET</b>	Anglais
M.	Jean-Pierre	<b>CHARPY</b>	Anglais
Mme	Catherine	<b>LEJEUNE</b>	Pôle Epidémiologie
M.	Gaëtan	<b>JEGO</b>	Biologie Cellulaire

### **PROFESSEURS DES UNIVERSITES**

Mme	Marianne	<b>ZELLER</b>	Physiologie
-----	----------	---------------	-------------

### **PROFESSEURS AGREGES de L'ENSEIGNEMENT SECONDAIRE**

Mme	Marceline	<b>EVRARD</b>	Anglais
Mme	Lucie	<b>MAILLARD</b>	Anglais

### **PROFESSEURS CERTIFIES**

Mme	Anaïs	<b>CARNET</b>	Anglais
M.	Philippe	<b>DE LA GRANGE</b>	Anglais
Mme	Virginie	<b>ROUXEL</b>	Anglais (Pharmacie)

### **PROFESSEURS DES UNIVERSITES - PRATICIENS HOSPITALIERS DES DISCIPLINES PHARMACEUTIQUES**

Mme	Evelyne	<b>KOHLI</b>	Immunologie
M.	François	<b>GIRODON</b>	Sciences biologiques, fondamentales et cliniques

### **MAITRES DE CONFERENCES DES UNIVERSITES PRATICIENS HOSPITALIERS DES DISCIPLINES PHARMACEUTIQUES**

M.	Mathieu	<b>BOULIN</b>	Pharmacie clinique
M.	Philippe	<b>FAGNONI</b>	Pharmacie clinique
M.	Frédéric	<b>LIRUSSI</b>	Toxicologie
M.	Marc	<b>SAUTOUR</b>	Botanique et cryptogamie
M.	Antonin	<b>SCHMITT</b>	Pharmacologie

***NOTE A INSERER APRES LA LISTE DU PERSONNEL DE L'UFR DES SCIENCES DE SANTE,  
CIRCONSCRIPTION MEDECINE***

L'UFR des Sciences de Santé de Dijon, Circonscription Médecine, déclare que les opinions émises dans les thèses qui lui sont présentées doivent être considérées comme propres à leurs auteurs, et qu'elle n'entend ne leur donner ni approbation, ni improbation.

**COMPOSITION DU JURY**

- Président :
  - Monsieur le Professeur Denis KRAUSE
  
- Membres :
  - Madame le Professeur Christiane MOUSSON
  - Monsieur le Professeur Luc CORMIER
  - Monsieur le Professeur Romaric LOFFROY  
(directeur de thèse)
  - Monsieur le Docteur Emmanuel DELORME

## **SERMENT D'HIPPOCRATE**

*"Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité.*

*Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux.*

*Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions.*

*J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité.*

*Même sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l'humanité.*

*J'informerai les patients des décisions envisagées, de leurs raisons et de leurs conséquences.*

*Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences.*

*Je donnerai mes soins à l'indigent et à quiconque me les demandera.*

*Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire.*

*Admis(e) dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les mœurs.*

*Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément.*

*Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission. Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés.*

*J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité.*

*Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonoré(e) et méprisé(e) si j'y manque."*

## Table des matières

<b>Abréviations</b>	p 2
<b>Article Original en anglais</b>	p 3
Abstract	
Introduction	
Materials and methods	
Results	
Discussion	
Conclusions	
<b>Conclusions</b>	p 24
<b>Bibliographie (References)</b>	p 25
<b>Annexes</b>	
Tableaux	p 35
Stades des maladies rénales chroniques selon la National Kidney Foundation (NKF-KDOQI™)	p 39
Résultats des études récentes évaluant le traitement des angiomyolipomes rénaux par embolisation artérielle sélective	p 40
Figures	p 41

## **Abréviations**

**AML:** Angiomyolipoma

**TSC:** Tuberous sclerosis complex

**SAE:** Selective arterial embolization

**PEComas:** Perivascular Epithelioid Cell neoplasms

**mTOR:** Mammalian target of rapamycin

**EAML:** Epithelioid angiomyolipoma

**NSS:** Nephron sparing surgery

**CKD-EPI:** Chronic Kidney Disease-Epidemiology Collaboration

**CT:** Computed tomography

**MRI:** Magnetic resonance imaging

**HU:** Hounsfield Units

**Fr:** French

**PES:** Post-embolization syndrome

**NSAID:** Non-steroidal anti-inflammatory drugs

**US:** Ultrasonography

**RCC:** Renal cell carcinoma

**GFR:** Glomerular filtration rate

**NKF KDOQI:** National Kidney Foundation Kidney Disease Outcomes Quality Initiative

**CKD:** Chronic Kidney Disease

*Manuscript title*

**Selective arterial embolization in the management of renal angiomyolipomas: a retrospective study of 23 cases**

*Running title*

Arterial embolization for renal angiomyolipomas

*Authors and affiliations*

Florian Bardin <sup>(1)</sup>, Olivier Chevallier <sup>(1)</sup>, Aurélie Bertaut <sup>(2)</sup>, Emmanuel Delorme <sup>(3)</sup>, Morgan Moulin <sup>(4)</sup>, Pierre Pottecher <sup>(1)</sup>, Lucy Di Marco <sup>(1)</sup>, Sophie Gehin <sup>(1)</sup>, Eric Mourey <sup>(4)</sup>, Luc Cormier <sup>(4)</sup>, Christiane Mousson <sup>(5)</sup>, Marco Midulla <sup>(1)</sup>, Romaric Loffroy <sup>(1,6)</sup>

<sup>(1)</sup> Department of Vascular and Interventional Radiology, François-Mitterrand Teaching Hospital, University of Dijon School of Medicine, Dijon, France

<sup>(2)</sup> Department of Epidemiology and Biostatistics, Georges François Leclerc Center, Dijon, France

<sup>(3)</sup> Department of Urology, Sainte Marie Private Hospital, Chalon-sur-Saône, France

<sup>(4)</sup> Department of Urology and Andrology, François-Mitterrand Teaching Hospital, University of Dijon School of Medicine, Dijon, France

<sup>(5)</sup> Department of Nephrology and Renal Transplantation, François-Mitterrand Teaching Hospital, University of Dijon School of Medicine, Dijon, France

<sup>(6)</sup> LE2I UMR CNRS 6306, Arts et Métiers, University of Bourgogne Franche-Comté, Dijon, France

*Funding source*

None

***Corresponding author***

Prof. Romaric Loffroy, MD, PhD

Postal Address : Department of Vascular and Interventional Radiology, François-Mitterrand

Teaching Hospital, 14 Rue Paul Gaffarel, BP 77908, 21079 Dijon Cedex, France; LE2I UMR

CNRS 6306, Arts et Métiers, University of Bourgogne Franche-Comté, Dijon, France

Phone : +33 380 293 358

Fax : +33 380 293 680

E-mail : [romaric.loffroy@chu-dijon.fr](mailto:romaric.loffroy@chu-dijon.fr)

## **Abstract**

**Background:** Angiomyolipoma (AML) is the most common renal benign tumor. Treatment should be considered for symptomatic patients or for those at risk for complications, especially retroperitoneal bleeding which is correlated to tumor size, grade of the angiogenic component and to the presence of tuberous sclerosis complex (TSC). This study reports our single-center experience with the use of selective arterial embolization (SAE) in the management of symptomatic and asymptomatic renal AMLs.

**Methods:** In this retrospective mono-centric study, all demographic and imaging data, medical records, angiographic features, outpatient charts and follow-up visits of patients who underwent prophylactic or emergency SAE for AMLs between January 2005 and July 2016 were reviewed. Tumor size and treatment outcomes were assessed at baseline and after the procedure during follow-up. Computed tomography, magnetic resonance imaging or ultrasonography was used to evaluate AML shrinkage. Renal function was measured pre- and post-procedure.

**Results:** Twenty-three patients (18 females, 5 males; median age, 45 years; range, 19-85) who underwent SAE either to treat bleeding AML (n=6) or as a prophylactic treatment (n=17) were included. Overall, 34 AMLs were embolized. TSC status was confirmed for 6 patients. Immediate technical success rate was 96% and 4 patients benefitted from an additional procedure. Major complications occurred in 3 patients and minor post-embolization syndrome in 14 patients. The mean AML size reduction rate was 26.2% after a mean follow-up was 20.5 months (range, 0.5-56 months), and only non-TSC status was significantly associated with better shrinkage of tumor (P=0.022). Intralesional aneurysms were significantly more frequent in patients with hemorrhagic presentation (P=0.008). There was no change in mean creatinine level after SAE.

**Conclusions:** SAE is a safe and effective technique to manage renal AMLs as a preventive treatment as well as in emergency setting, with significant reduction in tumor size during follow-up. A multidisciplinary approach remains fundamental, especially for TSC patients. In addition to size, the presence of intralesional aneurysms should be considered in any prophylactic treatment decision.

### **Keywords**

Renal tumor, angiomyolipoma, bleeding patient, arterial embolization, outcomes, therapeutic response.

## **Introduction**

Angiomyolipoma (AML) is a benign renal tumor and the most common benign hamartomatous neoplasm accounting for 0.3 to 3% of all renal masses (1-3). They are more accurately characterized as PEComas (Perivascular Epithelioid Cell neoplasms) in pathology (4). They are composed of fat, blood vessels and smooth muscle in varying quantities and are commonly divided into sporadic and non-sporadic groups (5, 6). The sporadic group, accounting for approximately 80% of all cases, consists of solitary lesion which occurs predominantly in middle-aged women with a prevalence of 0.22% to 0.29% in females and 0.02% to 0.1% in males (7-10). The non-sporadic group is related to tuberous sclerosis complex (TSC), an autosomal dominant multi-organ phacomatosis predisposing to benign tumor formation with activation of the mammalian target of rapamycin (mTOR) pathway, and is also more frequent in women (11). Within this group, angiomyolipomas develop in 50% of all patients during their life time, are often larger, multiple, bilateral, symptomatic and lesions are likely to widespread (7, 8, 12, 13). TSC may also be associated with lymphangiomyomatosis, a progressive disease related to tuberous sclerosis, which usually affects the lungs of young women (14, 15). Although a large majority of AMLs with focal epithelioid components are benign, pure epithelioid renal AML (EAML), a rare subgroup characterized by the presence of epithelial cells staining strongly for melanoma-associated markers, may become locally invasive and spread by affecting renal veins and inferior vena cava (16). Those aggressive epithelioid “carcinoma-like” variants are highly cellular with very little or no fat, tend to be larger and may become symptomatic for the majority (17, 18). As a benign lesion, most renal AMLs are asymptomatic, have a slow and consistent growth rate and minimal morbidity (19). They often do not require any intervention. However, they can cause flank pain or palpable mass but the main complications are retroperitoneal bleeding

or bleeding into the urinary collection system, which can be life threatening. The bleeding tendency is related to the angiogenic component of the tumor that includes irregular and/or aneurysmal blood vessels (20). The major risk factors for bleeding are tumor size, grade of the angiogenic component, and the presence of TSC (8, 20). The European Association of Urology recommends active surveillance for most AMLs and treatment in case of pain, bleeding, or suspected malignancy. Prophylactic invasive procedures such as selective arterial embolization (SAE) and nephron sparing surgery (NSS) can be considered in large tumors, females of childbearing age as AMLs tend to grow in size and rupture during pregnancy because of their hormone sensitivity (21, 22) and when access to emergency care may be inadequate (23). SAE can be used for prophylaxis of high-risk tumor, for acute management of tumor bleeding, or as a preoperative adjunct treatment for surgery to prevent intraoperative blood loss (8, 20, 24, 25). This minimally invasive interventional radiology technique has become the primary treatment for AMLs since several years because it is less invasive than a surgical intervention and enables targeted treatment of bleeding vessels with a low risk of severe complications (20, 24-41). The objective of this retrospective mono-centric study was to present our 11-year experience with planned prophylactic and emergency SAE of renal AMLs by reviewing our institution's series of 23 patients and evaluating complications, outcomes and tumor size reduction after SAE.

## **Materials and methods**

### ***Patients***

All imaging studies and medical records of patients with AMLs treated with SAE in our institution were reviewed over an 11-year period between January 2005 and July 2016. An electronic search of our imaging database was performed and the initial patient list consisted

of all report queries of patients treated at our hospital who matched for the words “angiomyolipoma(s)”, “hemorrhage” and/or “embolization”. From this first list, patients who underwent prophylactic or emergency SAE for AMLs with follow-up imaging and clinical follow-up were included. Patients without follow-up or who underwent arteriography without embolization were excluded of the statistical analysis; it concerned only the patients for whom another therapeutic strategy was decided and not because of a technical failure. EAMLs confirmed by histology were also excluded as this tumor has totally different components and behavior.

### ***Demographic, clinical and biological data***

We reviewed the medical records of all subjects and recorded demographic data (age and gender), angiomyolipoma type (sporadic or TSC-related), location and number of lesions, intervention type (prophylactic or emergency), clinical symptoms and complications before and within 4 weeks after SAE (according to the Society of Interventional Radiology classification system for complications) (42), recurrence (defined as recurrent symptoms or increase in tumor size of > 2 cm on follow-up images requiring re-intervention) (27) and the need for further treatment independently of the reason. Serum creatinine levels were measured before SAE and during follow-up with Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) method for clearance calculation. TSC patients suitable for a trial with mTOR inhibitor (everolimus) were also considered.

### ***Diagnosis, tumor size measurement and embolization technique***

All AMLs were diagnosed with computed tomography (CT) and/or magnetic resonance imaging (MRI) on the basis of the presence of intra-tumoral fat without calcification or necrosis (43-45). Macroscopic fat appeared as areas with a density less than -20 Hounsfield

Units (HU) on non-enhanced CT or with cancellation of high signal intensity on T1-weighted MR images with fat saturation. In and opposed-phased chemical shift sequences were useful in low fat AMLs in which the aforementioned typical T1 findings were not readily apparent (46). Two cases were confirmed at histologic diagnosis after percutaneous needle biopsy because of lack of macroscopic fat within the lesion and one of them was an epithelioid variant.

Post-processing was performed on a syngo<sup>®</sup>.via workstation (Siemens Healthcare, Erlangen, Germany). All pre-SAE and follow-up images were reviewed by an experienced radiologist and each embolized tumor was measured using maximum diameter as previously applied in the literature (32, 47). For measurement, we used the last available imaging exam performed before SAE (CT or MRI). Depending on availability, three-dimensional (3D) reconstructions with maximum diameter, 3D volume and density histograms calculation were performed for the prophylactic group diagnosed and followed-up with the CT modality by using MM Oncology software (Siemens Healthcare). Intralesional aneurysms were measured on angiographic images, not only with automatic calibration but also with reference to guiding catheter and microcatheter sizes. When a patient was found to have multiple aneurysms, the largest one was selected for evaluation.

The treatment plan was based on multidisciplinary proposal by interventional radiologists, urologists and/or nephrologists. SAE was performed under local anesthesia through the common femoral artery using 4-5 Fr angiographic catheters and coaxial microcatheters. An aortogram was first obtained to locate the renal arteries and to determine the presence of accessory renal arteries or extra-renal feeding vessels. After aortography, selective renal angiography was performed to assess AML circulation and extension of tumoral vessels outside the normal nephrogram, aneurysms, active extravasation and vascular displacements by the tumor or retro-peritoneal hematoma in emergency cases. Next, supra-selective

catheterization of AML feeding vessels was performed using a coaxial microcatheter in order to spare as much renal parenchyma as possible. Various embolic materials were used alone or in combination as calibrated particles, liquid embolic agents and microcoils including: tris-acryl gelatin and polyphosphazene microspheres 100-700  $\mu\text{m}$  (Embosphere<sup>®</sup>/Embogold<sup>®</sup>, Biosphere Medical Inc-Merit Medical Inc; Embozene<sup>®</sup>, CeloNova-Boston Scientific), detachable microcoils (Detach-18<sup>®</sup>, Cook Medical Technologies LLC, William Cook Europe A/S; Interlock-18 Coil<sup>®</sup>, Boston Scientific Corporation), acrylic glue (N-butyl 2-cyanoacrylate, Glubran 2<sup>®</sup>, GEM Srl, Viareggio, Italy) mixed with ethiodized oil (Lipiodol<sup>®</sup> Ultrafluid, Guerbet, Aulnay-sous-Bois, France) in a 1:3 to 1:6 ratio, and Onyx<sup>®</sup> 18 (Covidien, Mansfield, MA). One covered stent (Fluency<sup>®</sup> Plus Endovascular Stent Graft 7-40mm, C.R. Bard, Inc) was used to exclude a small bleeding adrenal branch from the origin of a renal artery in one patient. Embolic materials were injected under fluoroscopic guidance and coils were used to occlude large aneurysmal formations that would have been unsuitable for particle embolization alone. Additional supplying branches were selectively catheterized and embolized until total devascularization. Technical success was defined as stasis of flow in arteries feeding the tumor and lack of opacification of AML on post-SAE angiogram (35, 41). After the procedure, patients embolized for preventive purpose were transferred to a urology department at our institution or in a referring hospital for 24-48h stay and usually discharged the day after embolization. Vital signs were monitored and post-embolization syndrome (PES) (low-grade fever, pain and vomiting 3-7 days after SAE) routinely treated with non-steroidal anti-inflammatory drugs (NSAID). Antibiotic prophylaxis was not given. Patients from the TSC group were admitted to the nephrology department which was the best qualified to monitor them. Finally, patients embolized in emergency were then referred to various departments, especially intensive care and surgical units.

### ***Follow-up***

Medical records, outpatient charts, follow-up visits and imaging were reviewed. All the patients without follow-up at our institution were contacted by phone or e-mail to evaluate their current medical status and the need for additional treatment. They also provided their latest biology and imaging follow-up. Most of the outpatients underwent follow-up by the urology and nephrology teams 3-6 months after the procedure and once a year thereafter. CT or MR follow-up was recommended three months after SAE and annually if no change or decrease in size was noted. Images were obtained at different institutions with different equipments and protocols. For measurement, we used the last imaging exam available (CT or MRI or US).

### ***Statistical analyses***

Qualitative variables were described as percentages and compared using exact Fisher test. Quantitative variables were described using means with standard deviations and medians with ranges. They were compared using the non-parametric Mann and Whitney test. Correlation between the tumor reduction and initial tumor size was determined using Pearson coefficient. P-values less than 0.05 were considered as significant. Analyses were performed using SAS<sup>®</sup> 9.3 (Statistical Analysis Software).

### **Results**

Figure 1 represents flow chart of cohort construction for statistical analyses. The demographic and clinical data are presented in Table 1. During an 11-year study period, 23 patients underwent SAE in emergency to treat bleeding AMLs (n=6) (Fig. 2) or as prophylactic treatment for high-risk AMLs (tumor size >4 cm, abnormal vasculature on CT, other

symptoms) (n=17) and could be followed-up. One small sporadic asymptomatic AML was not embolized because its feeding vessels could not be identified during the arteriography; a percutaneous radiofrequency ablation was performed instead (48, 49). We preferred a conservative approach by active surveillance for a second sporadic asymptomatic AML because of its very small angiomyomatous component. One embolized patient was excluded because he died from heart failure before the first imaging control. We decided to treat a small epithelioid variant with SAE as this sub-group tends to be locally invasive and become symptomatic and another small AML on the same patient due to its high vascular composition (40, 50). Additional percutaneous thermal ablation with microwaves was decided for the epithelioid variant because of its uncertain evolution. The first tumor was excluded from statistical analysis according to exclusion criteria (n tumors = 34) (Fig. 3). One patient had a single right kidney before treatment. As it is widely accepted that lesions over 4 cm are more likely to become symptomatic (>90%) and more likely to bleed (>50%), almost all sporadic lesions were embolized on the basis of the size only (51).

AMLs were successfully embolized for 22 patients in the first instance (96%) with immediate and complete devascularization on post-procedural aortogram and 4 re-embolizations were necessary during the follow-up because of incomplete embolization (n=1) or recurrence (2 bleeding AMLs and 1 re-growth). Microspheres and glue were the most frequent embolic agents used. Aneurysms were found in 8 tumors (Fig. 4). In our cohort, total nephrectomy was performed for one renal AML nine months after the primary treatment with SAE therapy because of poor functional parenchyma on follow-up.

Patient outcomes, follow-up times and changes in tumor sizes are presented in Table 2. The mean size of AMLs was 8.9 cm and the median size was 7.7 cm. Minor complications affected 14 patients with post-embolization syndrome (PES) treated with conservative measures (n=14), persistent hematuria (n=1) and pyelonephritis (n=1). Major complications

affected 3 patients with two renal abscesses formations 17 and 21 days after the procedure and one femoral false-aneurysm associated to renal abscess during hospitalization. Drainage of renal collections was proposed to the first and the second patient; they recovered well and were discharged after one week. A few days after embolization of femoral false-aneurysm and abscess drainage, the third patient unfortunately died from hemodynamic failure. One TSC patient deceased from tumoral brain hemorrhage 4 years after SAE and one patient from the sporadic AML group had a total contralateral nephrectomy for concomitant renal cell carcinoma (RCC). Recurrence affected three patients during follow-up and all of them were successfully re-embolized with good results. The efficacy of embolization was determined over a mean follow-up of 20.5 months (range 0.5 to 56 months). No patients were lost to follow-up. For measurement of tumor sizes before SAE, CT was used for 18 patients and MRI was used for 5 patients. For measurement of tumor sizes after SAE, CT was used for 15 patients, MRI was used for 6 patients and ultrasound was used for 2 patients. Seventeen patients had pre-existent reduction of glomerular filtration rate (GFR) with mild reduction for 13, moderate reduction for 3 and severe for 1 according to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) classification for Chronic Kidney Disease (CKD) (Annex 1). There was no change in creatinine mean level after SAE. Changes in AMLs size after SAE are summarized in Table 3; the mean AMLs size reduction was 2.1 cm (26.2%) (Table 2) and only non-TSC status was significantly associated with better shrinkage of the tumors ( $P=0.022$ ).

Hemorrhagic presentation was significantly more frequent in patients with intralesional aneurysms ( $P=0.0086$ ) (Table 4), with presence of aneurysms in 62.5% of patients embolized in emergency for hemorrhage and only one hemorrhagic case without aneurysm found on arteriography.

## **Discussion**

Prior to 1976, more than 90% of sporadic AMLs were treated with total nephrectomy, as a malignant lesion could not be excluded (48). With improvement of cross sectional imaging and even in cases of low-fat tumors, AMLs can now be confidently diagnosed with an MRI specificity of up to 99% (52-53). Since the first report by Adler et al in 1984 (54), transarterial embolization has increasingly been used to become the new standard for preventive or emergency treatment of AMLs with minimally invasive selective targeting of small arterial feeders (25-27, 36). Literature comparing nephrectomy and nephron sparing surgery with SAE in the management of AMLs is limited (3, 8, 55, 56) with medical and economic analyses favoring embolization in symptomatic renal AMLs or AMLs at risk of complications. Endovascular therapy for AMLs has less postoperative morbidity (6.9%) compared to partial nephrectomy (12%), with minimal invasiveness and shorter hospitalization (54, 57). It also allows rapid stabilization in cases of acute hemorrhage with optimal sparing of the normal renal parenchyma to maintain maximal renal function which is especially important in TSC patients. Surgery allows complete resection of the tumor and pathologic analysis to confirm diagnosis but remains quite difficult for AMLs in some cases with complex vascular anatomy, hilar location or for TSC-associated AMLs because of the multiplicity of the lesions (47). In the case of failure of primary or repeat SAE, nephron-sparing surgery might be considered (20, 58). In our series, only one patient had surgical resection decided by urologists after successful SAE because of poor residual functional parenchyma.

Literature about laparoscopic and percutaneous ablative therapies for AMLs is also limited and largely restricted to small and asymptomatic tumors. Radiofrequency ablation series demonstrate good results with few to no retreatments, minor complications and no

recurrences (median follow up of up to 45 months) (48, 49). To date, we have performed 6 radiofrequency ablations for asymptomatic AMLs in our center and one of them was considered due to lack of abnormal vessels on arteriography. Reports for the use of cryoablation for AMLs are actually limited to small series (59-61).

In every case, discussion between interventional radiologists and urologists is essential to determine the optimal management. For many years, the threshold diameter for prophylactic treatment has been 4 cm (7, 8, 48) since Oesterling et al (51) estimated that in lesions greater than 4 cm, 82-94% were symptomatic and 50-60% bled spontaneously. However, this historical threshold has since been discussed by authors recommending treatment for asymptomatic tumors larger than 6 (62) or 8cm (8, 63) as the rate of symptomatic AML > 4cm seems to have been over-evaluated in old series (64). Hocquelet et al (40) identified the percentage of fat content before SAE as a predictive factor of volume decrease in their series with a volume reduction significantly more important for AMLs with less than 50% of fat than for those with more than 50% of fat (84% vs. 50%;  $P < 0.00001$ ). In their multivariate analysis, the best predictive model for volume decrease included only the percentage fat content ( $R^2 = 0.61$ ;  $P < 0.0001$ ). Unfortunately, the small number of unenhanced CT scans available to calculate density histograms did not allow us to confirm this hypothesis. However, we believe that in addition to size, composition of AMLs should play an important role in the embolization indication and results because the angiomyogenic component is the main cause of bleeding complications and the target of embolization. Planché et al (49) observed that the angiomyogenic components disappeared faster after embolization than the fatty components, and that “fat-poor” AMLs exhibited a larger volume reduction after SAE compared to “fat-rich” AMLs. In our series, we took into consideration the amount of angiomyogenic component and decided to embolize a “fat-poor” AML < 4cm with less than

5% of fat. It was the best result of our study with total disappearance of the mass on follow-up imaging (Figure 2).

In the same patient, we also decided to embolize an epithelioid AML diagnosed by pathology. This independent rare subtype of AML has malignant potential and imaging characteristics similar to renal cell carcinoma (RCC). Some cases of epithelioid AML metastasized to the lung, liver or bone have been previously reported but our patient wasn't metastatic and was asymptomatic (65-67). As the proper treatment for epithelioid AML is still discussed, we decided to perform an additional thermal ablation of the tumor while other authors recommend a more aggressive strategy using surgery with or without chemotherapy (68).

Several studies have recently recommended active surveillance as initial treatment for asymptomatic or mildly symptomatic AMLs, even if they are >4 cm (59). Ouzaid et al (69) found that only 13 out of 38 patients with AML > 4 cm discontinued active surveillance after 4 years mean follow-up, arguing that treatment for all tumors > 4 cm would have resulted in a 65% over-treatment rate and that 67% of symptomatic patients were managed with active surveillance without complications. Bhatt et al (59) found in their series of 447 patients up to 70% of asymptomatic lesions > 4cm with no difference in growth rates for lesions > 4 cm and < 4 cm. They support the hypothesis that a small sub-group of "fast growers" tend to be significantly more symptomatic than "slow" or "non-growers" and should be aware of the risk of progression and bleeding. Recent studies have suggested that although tumor size is important, size of associated aneurysms may be more significant. Yamakado et al (27, 70) found using the conventional cut-off of 4 cm has significantly poorer specificity (38%) than aneurysm of 5 mm or larger (86%) and aneurysm size was the only factor significantly linked to rupture in their multiple regression analysis (P=0.001). Aneurysms may be seen on CT scans but small ones are more easily assessed by conventional angiography (71). In our series,

aneurysms were significantly more frequent in hemorrhagic patients ( $P=0.0086$ ), confirming the importance of tumor composition.

A recent strategy for managing AML in patients with TSC is based on the use of targeted therapeutics focused on inhibition of the mTOR (Mammalian Target of Rapamycin) pathway to stop tumor progression and even promote regression of tumors. The first mTOR inhibitor tried was sirolimus, also known as rapamycin, initially developed as an immunosuppressive agent in solid organ transplantations. Everolimus is a rapamycin derivative that has been recently studied with data from two randomized controlled trials suggesting safety and efficacy (72, 73). EXIST-2, a double-blind-randomized controlled trial that included 118 patients with 3 cm or larger AMLs in the setting of TSC, randomized everolimus and placebo (67). At a median interval of 38 weeks there was a 42 % response rate for the everolimus group (95 % Confidence Interval (CI) 31-53%) versus 0 % for the placebo group (95% CI 0-9 %) with a response defined as a 50% or greater reduction in total AMLs volume. Median time to response for everolimus was 2.9 months and median exposure was 8.7 months. Progression-free rates for everolimus and placebo, respectively, were 92% (95% CI 65-98 %) and 25 % (95% CI 1-64 %) at 12 months and no patients who achieved a response in AML volume reduction progressed. A longer-term analysis of everolimus treatment demonstrated stability of everolimus effects over time with an improvement in response rate to 54 % (median exposure 28.9 months) (74). Angiomyolipoma shrinkage continued over time and no hemorrhage occurred. Six patients (5.4 %) presented angiomyolipoma progression at any time of the study.

Four of the 6 TSC patients in our SAE series received everolimus and it is difficult to determine which treatment had the greatest impact on the change in tumor size. Among those patients, one patient presented a 17% increasing size of tumors (sum of maximal diameters) after a 56 months follow-up and the three others presented respectively a 36%, 44% and 13%

shrinkage (49, 36 and 1 months follow-up). The first patient had severe renal impairment before treatments with stage 4 CKD and unfortunately progressed to stage 5. The second patient had stage 2 CKD before treatments and progressed to stage 3 with one single kidney before any therapeutics whereas the third maintained stage 2 CKD. The fourth patient did not have any renal impairment before and after treatments. Severe renal impairments (GFR <30 mL/min/1.73 m<sup>2</sup>) were observed in seven (6.3%) patients at least once post-baseline in EXIST-2 trial but all of these patients had compromised renal function (GFR <60 mL/min/1.73 m<sup>2</sup>) prior to everolimus initiation. No patients had stage 3/4 elevated serum creatinine, but 15 (13.4%) patients had stage 1/2 elevations.

Though these trials suggest safety and efficacy of everolimus in decreasing AML tumor and preventing progression in TSC population, its role remains to be investigated. Indeed, there is no study to our knowledge comparing SAE and mTOR only treatment. Moreover, the role of mTOR in the management of non-TSC associated AML remains to be determined.

In our series, two TSC patients presenting large AMLs were managed with SAE only. A 13% and 15% decrease was respectively observed with stage 3 and 2 CKD before treatment. No CKD progression was noticed for the first patient and the second patient presented a surprising renal function improvement after SAE. We explain these changes by the fact that we used only two renal function values for reference: the last available value before treatment and the last available value during the follow-up. Renal clearance is a complex variable influenced by many exogenous and endogenous events and it is hard to determine whether the treatment or this multi-organ disease had the most influence on renal function in our limited study population. In their 16 TSC-patients-only AML embolization series, Williams et al (30) found no statistically significant change in GFR after embolization with a mean interval between the procedure and the most recent renal function measurement of 23 months. Mean GFR before embolization was 95.75 mL/min/1.73 m<sup>2</sup>. Their study suggest efficiency and

safety of SAE to treat AML in TSC patient by preserving renal function which is very important in this population but the evolution of GFR seems to be uncertain once it has begun to deteriorate. Villalta et al (39) found no difference in tumor reduction size in patients with or without TSC. We observed significantly better tumors shrinkage in non-TSC patients after SAE (P=0.022) than in TSC-patients, suggesting the importance of combining different therapeutic strategies to obtain similar results in TSC patients.

We encountered low complication rates as it has been described in the past series (Annex 2). Only 3 patients presented severe complications. One false-aneurysm of the common femoral artery was successfully embolized and three abscesses formation following necrosis and liquefaction of tumors after SAE were managed with percutaneous drainage (75). As expected, post-embolization syndrome (PES), an inflammatory response causing pain and fever that can last for several days following SAE, was the main minor complication. Every patient pain and/or fever was easily managed with analgesics. Bissler et al (76) described the use of a short-term tapering dose of prednisone over a 2-week period after SAE of AMLs instead of acetaminophen and it appeared to reduce PES and improved patient comfort.

Since Han et al (24) and Lee et al (25) mostly used iodized oil mixed with absolute ethanol in their 90's series, many authors adopted this approach until Rimon et al (13) reached a 94% clinical success rate by adding polyvinyl alcohol (PVA) at completion. In our series, we used various embolic agents since studies comparing smaller and larger embolic agents for AMLs embolization did not find difference in tumor reduction size or need for repeat embolization (39). However, we're using more and more N-butyl-2 cyanoacrylate glue (Glubran®2) for SAE these last years. Property of glue for arterial occlusion is mostly seen in lesions supplied by end-arteries; as a consequence, intra-parenchymal tumors or vascular lesions with end-artery feeders such as AMLs are suitable for glue application, with the expectation of a sclerosis of the tumor and a total devascularization of the vascular bed (77). Advantages of

glue are that it works instantly, provides fast and distal embolization with high dilution of Lipiodol (ratio glue:lipiodol >1:5), completely occludes vessels and is permanent (78). It is also cheap and easy to use mixed with ethiodized oil (Lipiodol), making easier to see the progression of glue in the vascular feeders and to visualize reflux along the microcatheter, which can reduce the risk of gluing the tip of the microcatheter and injecting glues into normal renal parenchyma. No series have described the use of glue in such a setting whereas it combines many advantages over other embolic agents, even if a learning curve is mandatory.

This study has some limitations. First, this is a retrospective study with a small size cohort due to the rarity of large and/or symptomatic AMLs. Our population was heterogeneous with sporadic cases (n=17), TSC patients (n=6) and different presentations (preventive vs emergency embolization). Second, as in other studies, we encountered difficulty to measure with accuracy large AMLs associated with retroperitoneal hemorrhage, especially as several modalities were used (US, CT and MRI). In particular, data were difficult to measure in cases of AML ruptures, which was often the mode of revelation of emergency cases. In addition, the follow-up images of some patients were obtained from other hospitals with different equipments than that available in our hospital. However, no patients were lost during follow-up in this study. Variable follow-up (mean follow-up of 20.5 months (range 0.5-56 months)) should not impact the findings of our study since the majority of AMLs shrinkage occurs within the first years following SAE (79). This was confirmed for the last two patients of our series with only short term follow-up images available; the first one presented a 8% and 9% tumors shrinkage one month after treatment and the second an impressive 48% decreased two months after embolization. With 13% of complications, 13% of recurrence and 17% of repeated embolization, our results are comparable to those previously reported in the literature and summarized in Annex 2.

## **Conclusions**

SAE is an effective technique to manage AMLs preventively or in emergency to treat bleeding, with substantial reduction in tumor size, low recurrence rates and acceptable complications. We found a larger tumor reduction size for sporadic AMLs, stressing the importance of a multidisciplinary approach to AMLs associated to TSC which are usually bigger, multiple and consequently harder to manage. This study emphasizes the role of tumor composition and especially the presence of intratumoral aneurysms which was significantly more frequent in hemorrhagic tumors. As a consequence, we believe that in addition to size, the initial composition of the tumor should be considered in treatment decision. Further studies are needed to clarify the precise role of all therapeutic modalities currently available, especially in TSC patients.

## **Consent section**

Written informed consent was obtained from all patients for publication of this original series and any accompanying images.

## **Acknowledgements**

None.

## **Footnote**

*Conflicts of Interest:* The authors have no conflicts of interest to declare.

*Ethical Statement:* Ethics Committee Approval of the institution was waived because the endovascular procedures were routinely performed as part of clinical practice. Written informed consent was obtained from all patients.

**UNIVERSITE DE BOURGOGNE**  
**THESE SOUTENUE PAR M BARDIN FLORIAN**

**CONCLUSIONS**

L'auteur présente sa thèse de Doctorat en Médecine sous forme d'un article original en anglais rapportant l'expérience dijonnaise du traitement prophylactique ou en urgence des angiomyolipomes rénaux par embolisation artérielle sélective. Cette modalité thérapeutique s'est imposée comme la technique de référence ces vingt dernières années pour le traitement d'angiomyolipomes sporadiques ou associés à la sclérose tubéreuse de Bourneville grâce à une procédure efficace, suivie d'une hospitalisation souvent courte avec une faible morbi-mortalité.

Ce premier travail portant sur une cohorte observationnelle analysée de façon rétrospective, permettra par la suite la réalisation d'études de plus grande ampleur au sein de notre service ou multicentriques.


L'analyse des résultats souligne le taux de succès élevé de cette procédure avec un taux faible de récurrences et de complications sévères. Elle précise l'importance de la composition tumorale, à intégrer dans la décision thérapeutique en complément de la taille des angiomyolipomes, notamment de la présence significativement plus élevées d'anévrismes au sein des tumeurs hémorragiques. La discussion propose une analyse comparative aux données récentes de la littérature.

Cette étude conforte l'idée qu'une prise en charge optimale des tumeurs associées à la sclérose tubéreuse de Bourneville, de décroissance significativement moindre dans notre série après traitement endovasculaire comparativement aux tumeurs sporadiques, implique une collaboration pluridisciplinaire entre radiologues interventionnels, urologues et néphrologues afin d'adapter au mieux la thérapeutique de ces patients.

Cette série ouvre des perspectives pour d'autres modalités thérapeutiques des angiomyolipomes en radiologies interventionnelle, notamment par thermo-ablation.

Cet article fera l'objet d'une publication dans une revue internationale.

Le Président du jury,

  
Dr. D. Krauss

Vu et permis d'imprimer

Dijon, le 16 SEPTEMBRE 2016

Le Doyen

  
Pr. F. HUËT

## References

1. Hajdu SI, Foote FW. Angiomyolipoma of the kidney: report of 27 cases and review of the literature. *J Urol* 1969;102:396-401.
2. Soulen MC, Faykus Jr. MH, Shlansky-Goldberg RD, Wein AJ, Cope C. Elective embolization for prevention of hemorrhage from renal angiomyolipomas. *J Vasc Interv Radiol* 1994;5:587-91.
3. Koo KC, Kim WT, Ham WS, Lee JS, Ju HJ, Choi YD. Trends of presentation and clinical outcome of treated renal angiomyolipoma. *Yonsei Med J* 2010;51:728-34.
4. Zhao Y, Bui MM, Spiess PE, Dhillon J. Sclerosing PEComa of the kidney: clinicopathologic analysis of 2 cases and review of the literature. *Clin Genitourin Cancer* 2104;12:e229-32.
5. Morgan GS, Straumfjord JV, Hall EJ. Angiomyolipoma of the kidney. *J Urol* 1951;65:525-7.
6. Sherman JL, Hartman DS, Friedman AC, Madewell JE, Davis CJ, Goldman SM. Angiomyolipoma: computed tomographic-pathologic correlation of 17 cases. *AJR Am J Roentgenol* 1981;137:1221-6.
7. Steiner MS, Goldman SM, Fishman EK, Marshall FF. The natural history of renal angiomyolipoma. *J Urol* 1993;150:1782-6.
8. Nelson CP, Sanda MG. Contemporary diagnosis and management of renal angiomyolipoma. *J Urol* 2002;168:1315-25.
9. Pfister C, Thoumas D, Fauquet I. Diagnostic and therapeutic approach of angiomyolipoma. *Prog Urol* 2002;12:108-13.
10. Fujii Y, Ajima J, Oka K, Tosaka A, Takehara Y. Benign renal tumors detected among healthy adults by abdominal ultrasonography. *Eur Urol* 1995;27:124-7.

11. Bissler JJ, Kingswood JC. Renal angiomyolipomata. *Kidney Int* 2004;66:924-34.
12. Harabayashi T, Shinohara N, Katano H, Nonomura K, Shimizu T, Koyanagi T. Management of renal angiomyolipomas associated with tuberous sclerosis complex. *J Urol* 2004;171:102-5.
13. Rimon U, Duvdevani M, Garniek A, Golan G, Bensaid P, Ramon J, Morag B. Large renal angiomyolipomas: digital subtraction angiographic grading and presentation with bleeding. *Clin Radiol* 2006;61:520-6.
14. Rumancik WM, Bosniak MA, Rosen RJ, Hulnick D. Atypical renal and pararenal hamartomas associated with lymphangiomyomatosis. *AJR Am J Roentgenol* 1984;142:971-2.
15. Tobino K, Johkoh T, Fujimoto K, Sakai F, Arakawa H, Kurihara M, Kumasaka T, Koike K, Takahashi K, Seyama K. Computed tomographic features of lymphangiomyomatosis: evaluation in 138 patients. *Eur J Radiol* 2015;84:534-41.
16. Warakaulle DR, Phillips RR, Turner GDH, Davies D, Protheroe AS. Malignant monotypic epithelioid angiomyolipoma of the kidney. *Clin Radiol* 2004 Sep;59:849-52.
17. Islam AH, Ehara T, Kato H, Hayama M, Kashiwabara T, Nishizawa O. Angiomyolipoma of kidney involving the inferior vena cava. *Int J Urol* 2004;11:897-902.
18. Tsai CC, Wu WJ, Li CC, Wang CJ, Wu CH, Wu CC. Epithelioid angiomyolipoma of the kidney mimicking renal cell carcinoma: a clinicopathologic analysis of cases and literature review. *Kaohsiung J Med Sci* 2009;25:133-40.
19. Mues AC, Palacios JM, Haramis G, Casazza C, Badani K, Gupta M, McKiernan J, Benson MC, Landman J. Contemporary experience in the management of angiomyolipoma. *J Endourol* 2010;24:1883-6.

20. Ramon J, Rimon U, Garniek A, Golan G, Bensaid P, Kitrey ND, Nadu A, Dotan ZA. Renal Angiomyolipoma: Long-term results following selective arterial embolization. *Eur Urol* 2009;55:1155-62.
21. Preece P, Mees B, Norris B, Christie M, Wagner T, Dundee P. Surgical management of haemorrhaging renal angiomyolipoma in pregnancy. *Int J Surg Case Rep* 2015;7C:89-92.
22. Boorjian SA, Sheinin Y, Crispin PL, Lohse CM, Kwon ED, Leibovich BC. Hormone receptor expression in renal angiomyolipoma: clinicopathologic correlation. *Urology* 2008;72:927-32.
23. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A. EAU guidelines on renal cell carcinoma: 2014 update. *Eur Urol* 2015;67:913-24.
24. Han YM, Kim JK, Roh BS, Song HY, Lee JM, Lee YH, Chung GH, Kim CS, Sohn MH, Choi KC. Renal angiomyolipoma: selective arterial embolization--effectiveness and changes in angiomyogenic components in long-term follow-up. *Radiology* 1997;204:65-70.
25. Lee W, Kim TS, Chung JW, Han JK, Kim SH, Park JH. Renal angiomyolipoma: embolotherapy with a mixture of alcohol and iodized oil. *J Vasc Interv Radiol* 1998;9:255-61.
26. Ewalt DH, Diamond N, Rees C, Sparagana SP, Delgado M, Batchelor L, Roach ES. Long-term outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis complex. *J Urol* 2005;174:1764-6.
27. Kothary N, Soulen MC, Clark TWI, Wein AJ, Shlansky-Goldberg RD, Stavropoulos SW. Renal angiomyolipoma: long-term results after arterial embolization. *J Vasc Interv Radiol* 2005;16:45-50.

28. Rimon U, Duvdevani M, Garniek A, Golan G, Bensaid P, Ramon J, Morag B. Ethanol and polyvinyl alcohol mixture for transcatheter embolization of renal angiomyolipoma. *AJR Am J Roentgenol* 2006;187:762-8.
29. Dabbeche C, Chaker M, Chemali R, Perot V, Hajj L El, Ferriere JM, Ballanger P, Chabbert V, Cimpean A, Otal P, Huyghe E, Grenier N, Joffre F. Role of embolization in renal angiomyolipomas. *J Radiol* 2006;87:1859-67.
30. Williams JM, Racadio JM, Johnson ND, Donnelly LF, Bissler JJ. Embolization of renal angiomyolipomata in patients with tuberous sclerosis complex. *Am J Kidney Dis* 2006;47:95-102.
31. Lenton J, Kessel D, Watkinson AF. Embolization of renal angiomyolipoma: immediate complications and long-term outcomes. *Clin Radiol* 2008;63:864-70.
32. Lee SY, Hsu HH, Chen YC, Huang CC, Wong YC, Wang LJ, Chuang CK, Yang CW. Embolization of renal angiomyolipomas: short-term and long-term outcomes, complications, and tumor shrinkage. *Cardiovasc Intervent Radiol* 2009;32:1171-8.
33. Sooriakumaran P, Gibbs P, Coughlin G, Attard V, Elmslie F, Kingswood C, Taylor J, Corbishley C, Patel U, Anderson C. Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. *BJU Int* 2010;105:101-6.
34. Tillou X, Boutemy F, Remond A, Petit J. Contribution of curative and preventive embolization for renal angiomyolipomas treatment. *Prog Urol* 2010;20:627-32.
35. Bishay VL, Crino PB, Wein AJ, Malkowicz SB, Trerotola SO, Soulen MC, Stavropoulos SW. Embolization of giant renal angiomyolipomas: technique and results. *J Vasc Interv Radiol* 2010;21:67-72.
36. Chick CM, Tan BS, Cheng C, Taneja M, Lo R, Tan YH. Long-term follow-up of the treatment of renal angiomyolipomas after selective arterial embolization with alcohol. *BJU Int* 2010;105:390-4.

37. Chan CK, Yu S, Yip S, Lee P. The efficacy, safety and durability of selective renal arterial embolization in treating symptomatic and asymptomatic renal angiomyolipoma. *Urology* 2011;77:642-8.
38. Stoica G, Kheir C, Schöenig A, Chabrot P, Cassagnes L, Ravel A, Boiteux JP, Guy L, Boyer L. Preventive and emergency embolization of angiomyolipomas: our experience. *Prog Urol* 2011;21:514-20.
39. Villalta JD, Sorensen MD, Durack JC, Kerlan RK, Stoller ML. Selective Aarterial embolization of angiomyolipomas: a comparison of smaller and larger embolic agents. *J Urol* 2011;186:921-7.
40. Hocquelet A, Cornelis F, Le Bras Y, Meyer M, Tricaud E, Lasserre AS, Ferrière JM, Robert G, Grenier N. Long-term results of preventive embolization of renal angiomyolipomas: evaluation of predictive factors of volume decrease. *Eur Radiol* 2014;24:1785-93.
41. Duan XH, Zhang MF, Ren JZ, Han XW, Chen PF, Zhang K, Jia ZL. Urgent transcatheter arterial embolization for the treatment of ruptured renal angiomyolipoma with spontaneous hemorrhage. *Acta Radiol* 2015 [Epub ahead of print].
42. Omary RA, Bettmann MA, Cardella JF, Bakal CW, Schwartzberg MS, Sacks D, Rholl KS, Meranze SG, Lewis CA; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for the reporting and archiving of interventional radiology procedures. *J Vasc Interv Radiol* 2003;14:S293-5.
43. Simpson E, Patel U. Diagnosis of angiomyolipoma using computed tomography-region of interest  $\leq -10$  HU or 4 adjacent pixels  $\leq -10$  HU are recommended as the diagnostic thresholds. *Clin Radiol* 2006;61:410-6.

44. Davenport MS, Neville AM, Ellis JH, Cohan RH, Chaudhry HS, Leder RA. Diagnosis of renal angiomyolipoma with hounsfield unit thresholds: effect of size of region of interest and nephrographic phase imaging. *Radiology* 2011;260:158-65.
45. Kim JK, Kim SH, Jang YJ, Ahn H, Kim CS, Park H, Lee JW, Kim S, Cho KS. Renal angiomyolipoma with minimal fat: differentiation from other neoplasms at double-echo chemical shift FLASH MR imaging. *Radiology* 2006;239:174-80.
46. Israel GM, Hindman N, Hecht E, Krinsky G. The use of opposed-phase chemical shift MRI in the diagnosis of renal angiomyolipomas. *AJR Am J Roentgenol* 2005;184:1868-72.
47. Seyam RM, Bissada NK, Kattan SA, Mokhtar AA, Aslam M, Fahmy WE, Mourad WA, Binmahfouz AA, Alzahrani HM, Hanash KA. Changing trends in presentation, diagnosis and management of renal angiomyolipoma: comparison of sporadic and tuberous sclerosis complex-associated forms. *Urology* 2008;72:1077-82.
48. Castle SM, Gorbatiy V, Ekwenna O, Young E, Leveillee RJ. Radiofrequency ablation (RFA) therapy for renal angiomyolipoma (AML): an alternative to angio-embolization and nephron-sparing surgery. *BJU Int* 2012;109:384-7.
49. Tan YK, Best SL, Olweny E, Park S, Trimmer C, Cadeddu JA. Radiofrequency ablation of incidental benign small renal mass: outcomes and follow-up protocol. *Urology* 2012;79:827-30.
50. Planché O, Correas JM, Mader B, Joly D, Méjean A, Hélénon O. Prophylactic embolization of renal angiomyolipomas: evaluation of therapeutic response using CT 3D volume calculation and density histograms. *J Vasc Interv Radiol* 2011;22:1388-95.
51. Oesterling JE, Fishman EK, Goldman SM, Marshall FF. The management of renal angiomyolipoma. *J Urol* 1986;135:1121-4.
52. Lienert AR, Nicol D. Renal angiomyolipoma. *BJU Int* 2012;110:25-7.

53. Sasiwimonphan K, Takahashi N, Leibovich BC, Carter RE, Atwell TD, Kawashima A. Small (<4 cm) renal mass: differentiation of angiomyolipoma without visible fat from renal cell carcinoma utilizing MR imaging. *Radiology* 2012;263:160-8.
54. Adler J, Greweldinger J, Litzky G. “Macro” aneurism in renal angiomyolipoma: two cases, with therapeutic embolization in one patient. *Urol Radiol* 1984;6:201-3.
55. Huyghe E, Dechier MC, Mottier ML, Rischmann P, Otal P, Soulie M, Plante P, Joffre F. Management of renal angiomyolipoma: medical and cost effectiveness comparison of selective embolization and surgery. *J Urol* 2010;183:e527.
56. Faddegon S, So A. Treatment of angiomyolipoma at a tertiary care centre: the decision between surgery and angioembolization. *Can Urol Assoc J* 2011;5:E138-41.
57. Boorjian SA, Frank I, Inman B, Lohse CM, Cheville JC, Leibovich BC, Blute ML. The role of partial nephrectomy for the management of sporadic renal angiomyolipoma. *Urology* 2007;70:1064-8.
58. De Luca S, Terrone C, Rossetti SR. Management of renal angiomyolipoma: a report of 53 cases. *BJU Int* 1999;83:215-8.
59. Byrd GF, Lawatsch EJ, Mesrobian HG, Begun F, Langenstroer P. Laparoscopic cryoablation of renal angiomyolipoma. *J Urol* 2006;176:1512-6.
60. Krummel T, Garnon J, Lang H, Gangi A, Hannedouche T. Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition. *BMC Urol* 2014;14:77.
61. Trelborg K, Nielsen TK, Østraat EØ, Olsen LH. Laparoscopic cryoablation of angiomyolipomas in adolescents and young adults: A report of four cases associated with tuberous sclerosis and 1 case of sporadic origin. *J Pediatr Urol* 2016 [Epub ahead of print].

62. Kuusk T, Biancari F, Lane B, Tobert C, Campbell S, Rimon U, D'Andrea V, Mehik A, Vaarala MH. Treatment of renal angiomyolipoma: pooled analysis of individual patient data. *BMC Urol* 2015;15:123.
63. Dickinson M, Ruckle H, Beagler M, Hadley HR. Renal angiomyolipoma: optimal treatment based on size and symptoms. *Clin Nephrol* 1998;49:281-6.
64. Bhatt JR, Richard PO, Kim NS, Finelli A, Manickavachagam K, Legere L, Evans A, Pei Y, Sykes J, Jhaveri K, Jewett MA. Natural history of renal angiomyolipoma (AML): most patients with large AMLs >4cm can be offered active surveillance as an initial management strategy. *Eur Urol* 2016 [Epub ahead of print].
65. Lau SK, Marchevsky AM, McKenna RJ, Luthringer DJ. Malignant monotypic epithelioid angiomyolipoma of the retroperitoneum. *Int J Surg Pathol* 2003;11:223-8.
66. Huang KH, Huang CY, Chung SD, Pu YS, Shun CT, Chen J. Malignant epithelioid angiomyolipoma of the kidney. *J Formos Med Assoc* 2007;106:S51-4.
67. Guo B, Song H, Yue J, Li G. Malignant renal epithelioid angiomyolipoma: A case report and review of the literature. *Oncol Lett* 2016;11:95-8.
68. Vicens RA, Jensen CT, Korivi BR, Bhosale PR. Malignant renal epithelioid angiomyolipoma with liver metastasis after resection: a case report with multimodality imaging and review of the literature. *J Comput Assist Tomogr* 2014;38:574-77.
69. Ouzaid I, Autorino R, Fatica R, Herts BR, McLennan G, Remer EM, Haber GP. Active surveillance for renal angiomyolipoma: outcomes and factors predictive of delayed intervention. *BJU Int* 2014;114:412-7.
70. Yamakado K, Tanaka N, Nakagawa T, Kobayashi S, Yanagawa M, Takeda K. Renal angiomyolipoma: relationships between tumor size, aneurism formation, and rupture. *Radiology* 2002;225:78-82.

71. Yip KH, Peh WC, Tam PC. Spontaneous rupture of renal tumours: the role of imaging in diagnosis and management. *Br J Radiol* 1998;71:146-54.
72. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittmore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet* 2013;381:817-24.
73. Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM, Korf BR, Flamini JR, Kohrman MH, Sparagana SP, Wu JY, Brechenmacher T, Stein K, Berkowitz N, Bissler JJ, Franz DN. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. *Nephrol Dial Transplant* 2014;29:1203-10.
74. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Berkowitz N, Miao S, Segal S, Peyrard S, Budde K. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangiomyomatosis: extension of a randomized controlled trial. *Nephrol Dial Transplant* 2016;31:111-9.
75. Ozkara H, Ozkan B, Solok V. Management of renal abscess formation after embolization due to renal angiomyolipomas in two cases. *Int Urol Nephrol* 2006;38:427-9.
76. Bissler JJ, Racadio J, Donnelly LF, Johnson ND. Reduction of postembolization syndrome after ablation of renal angiomyolipoma. *Am J Kidney Dis* 2002;39:966-71.

77. Ginat DT, Saad WEA, Turba UC. Transcatheter renal artery embolization: clinical applications and techniques. *Tech Vasc Interv Radiol* 2009;12:224-39.
78. Vaidya S, Tozer KR, Chen J. An overview of embolic agents. *Semin Intervent Radiol* 2008;25:204-15.
79. Patatas K, Robinson GJ, Ettles DF, Lakshminarayan R. Patterns of renal angiomyolipoma regression post embolisation on medium- to long-term follow-up. *Br J Radiol* 2013;86:20120633.

## Tables

**Table 1. Patient demographic and clinical data.**

Variables	Data
No. of patients	23
Gender, n (%)	
Male	5 (22)
Female	18 (78)
Age at presentation, years	
Mean ( $\pm$ SD)	52 ( $\pm$ 19)
Median (range)	45 (19-85)
TSC status, n (%)	
Yes	6 (26.1)
No	17 (73.9)
Type of SAE, n (%)	
Prophylactic	17 (73.9)
Emergency	6 (26.1)
Indications, n (%)*	
Size only	13 (56.5)
Composition only**	1 (4.3)
Pain	7 (30.4)
Hematuria	4 (17.4)
Retroperitoneal bleeding	6 (26.1)
Type of AMLs, n (%)	
Unique	11 (47.8)
Multiple	12 (52.2)
Presentation of AMLs, n (%)	
Unilateral	14 (60.9)
Bilateral	9 (39.1)
Presence of aneurysms, n (%)	
Yes	8 (34.8)
No	15 (65.2)
No. of AMLs embolized	34
Type of AMLs, n (%)	
Tuberous sclerosis associated	17 (50)
Sporadic	17 (50)
Side of AMLs, n (%)	
Right	18 (78.3)
Left	16 (69.6)

*Footnote* : \*Possible multiple indications per patient; \*\*Size < 4 cm but « fat-poor AML » according to density histogram; TSC, tuberous sclerosis complex; SAE, selective arterial embolization; AMLs, angiomyolipomas

**Table 2. Outcomes, follow-up and changes in tumor sizes after SAE.**

Variables	Data
Size of AMLs before SAE, cm	
Mean ( $\pm$ SD)	8.9 ( $\pm$ 5)
Median (range)	6.7 (1-20.9)
Size of symptomatic AMLs before SAE, cm	
Mean ( $\pm$ SD)	12.4 ( $\pm$ )
Median (range)	11.1 (5-24.9)
Mean follow-up, months (range)	20.5 (0.5-56)
Tumor size reduction	
Mean, cm ( $\pm$ SD)	2.1 (2.1)
Mean rate, % ( $\pm$ SD)	26.2 ( $\pm$ 24.4)
Renal function, mL/min/1.73m <sup>2</sup>	
Before SAE, mean ( $\pm$ SD)	78 ( $\pm$ 21)
After SAE, mean ( $\pm$ SD)	77 ( $\pm$ 31)
Technical success rate of first embolization*, n (%)	22 (95.6)
Need for re-embolization, n (%)	4 (17.4)
Recurrence**, n (%)	3 (13)
Increase in size on follow-up	1 (4.3)
Recurrent bleeding symptoms	2 (8.7)
Need for renal surgery post-SAE, n (%)	1 (4.3)
Minor complications***, n (%)	14 (60.9)
PES	14 (60.9)
Hematuria	1 (4.3)
Nephritis	1 (4.3)
Major complications***, n (%)	3 (13)
Puncture site false aneurysm	1 (4.3)
Abscess	3 (13)
Death	1 (4.3)
Embolic material used****, n (%)	
Microspheres	16 (69.6)
Cyanoacrylate glue	10 (43.5)
Microcoils	3 (13)
Onyx	2 (8.7)
Covered stent	1 (4.3)
Everolimus treatment, n (%)	
Yes	4 (17.4)
No	19 (82.6)

*Footnote* : \*Defined as stasis of flow in arteries feeding the tumor and lack of opacification of AML on post-SAE angiogram; \*\*Defined as recurrent symptoms or increase in tumor size of > 2 cm on follow-up images requiring re-intervention; \*\*\*Defined as complications within 4 weeks of SAE (according to the Society of Interventional Radiology classification system for complications) with possible multiple complications per patient; \*\*\*\*Possible multiple embolic materials per patient; AMLs, angiomyolipomas; SAE, selective arterial embolization; PES, post-embolization syndrome

**Table 3. Comparison of changes in AMLs size after SAE according to presentation, type of SAE, presence of symptoms and aneurysms.**

Variables			Data					
	AMLs (n)	Size	Mean	SD	Median	Min.	Max.	P-value
<b>Sporadic</b>	17	TSR	3.1	2.3	2.4	0.6	8.6	0.0220
		TSR rate	35.5	21.7	32.9	7.9	100.0	
<b>TSC</b>	17	TSR	1.2	1.4	1.3	-1.3	4.0	
		TSR rate	16.9	24.0	16.1	-26.0	67.7	
<b>Prophylactic</b>	25	TSR	1.5	1.3	1.7	-1.3	3.7	0.8913
		TSR rate	25.9	26.7	28.0	-26.0	100.0	
<b>Emergency</b>	9	TSR	3.9	2.9	4.0	0.0	8.6	
		TSR rate	27.1	17.9	26.2	0.0	52.1	
<b>Symptomatic</b>	15	TSR	1.4	1.3	1.7	-1.3	3.7	0.5671
		TSR rate	27.8	29.8	28.0	-26.0	100.0	
<b>Asymptomatic</b>	19	TSR	3.1	2.5	2.7	0.0	8.6	
		TSR rate	24.2	16.0	26.2	0.0	52.1	
<b>Aneurysms</b>	8	TSR	2.5	2.8	1.5	-1.0	7.5	0.3101
		TSR rate	18.8	21.5	18.3	-18.9	48.4	
<b>No aneurysms</b>	26	TSR	2.0	1.8	1.9	-1.3	8.6	
		TSR rate	28.4	25.2	28.6	-26.0	100.0	

*Footnote* : AMLs, angiomyolipomas; SAE, selective arterial embolization; TSR, tumor size réduction in cm; TSR rate in %; SD, standard déviation; TSC, tuberous sclerosis complex

**Table 4. Relationship between AML hemorrhage and presence of intralesional aneurysms.**

	<b>Hemorrhage (n=6)</b>	<b>No hemorrhage (n=17)</b>	<b>P-value</b>
<b>Presence of aneurysms (n=8)</b>	5	3	0.0086
<b>Absence of aneurysms (n=15)</b>	1	14	

## Annexes

### Annex 1. Stages of Chronic Kidney Disease.

<b>Stage</b>	<b>Description</b>	<b>GFR (mL/min/1.73 m<sup>2</sup>)</b>
<b>1</b>	Kidney damage with normal or ↑ GFR	≥90
<b>2</b>	Kidney damage with mild ↓ GFR	60–89
<b>3</b>	Moderate ↓ GFR	30–59
<b>4</b>	Severe ↓ GFR	15–29
<b>5</b>	Kidney failure	<15 (or dialysis)

Chronic kidney disease is defined as either kidney damage or GFR <60 mL/min/1.73 m<sup>2</sup> for ≥3 months. Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies.

## Annex 2. Results of contemporary selective arterial embolization series for AMLs.

Series	Year	No. Patients	Mean tumor size (cm)	No. Complications (%)*	Recurrent hemorrhage or growth (%)	No. Repeat embolization (%)	No. Surgery (%)	Mean follow up (months)
<i>Han et al.</i>	1997	14	11 (range 4.0-35.0)	0	4 (28.6)	2 (14.3)	1 (7.1)	33
<i>Lee W. et al.</i>	1998	15	8.5 (range 6-15)	1 (6.7)	3 (20)	2 (13.3)	NA	35.6
<i>Ewalt et al.</i>	2005	16	NA (range 4-21)	2 (12.5)	0	2 (12.5)	NA	NA
<i>Kothary et al.</i>	2005	19	NA	0	6 (31.6)	6 (31.6)	NA	51.5
<i>Rimon et al.</i>	2006	17	10 (range 5.5-20)	0	1 (5.8)	11 (64.7)	1 (5.9)	22.4
<i>Dabbech et al.</i>	2006	34	7.8 (emergency, range 4.5-18); 5.3 (preventive, range 4-11)	10 (29.4)	7 (20.6)	4 (11.8)	12 (35.3)	21
<i>Williams et al.</i>	2006	16	Vol. 314.99 cm3 (range 27.83-814.43 cm3)	3 (18.75)	1 (6.25)	NA	NA	40
<i>Lenton et al.</i>	2008	17	NA	NA	5 (29.4)	5 (29.4)	NA	NA
<i>Lee SY. et al.</i>	2009	11	8.57±2.66	1 (9.1)	2 (18.2)	1 (9.1)	1 (9.1)	28.2
<i>Ramon et al.</i>	2009	41	10.3 (range 10.0-25.0)	8 (19.5)	16 (39.0)	15 (36.6)	3 (7.3)	57.6
<i>Sooriakumaran et al.</i>	2009	19	12.5 (TSC-median size)	3 (15.8)	8 (42.1)	NA	NA	NA
<i>Tillou et al.</i>	2009	21	7 (2-13)	2 (9.5)	0	1	7 (33.3)	53.2
<i>Bishay et al.</i>	2010	16	15.0 (range 10.0-25.0)	2 (12.0)	3 (18.8)	9 (56.3)	0	29.0
<i>Chick et al.</i>	2010	34	11.9 (range 4.0-30.0)	1 (2.9)	5 (14.7)	2 (5.9)	2 (5.9)	44.2
<i>Chan et al.</i>	2011	27	10.9 (range 4.0-30.0)	0	6 (22.2)	4 (14.8)	4 (14.8)	85.2
<i>Stoica et al.</i>	2011	20	8.2±2.8 (emergency) 5.2±2.2 (preventive)	0	3 (15)	2 (10)	1 (5)	NA
<i>Villalta et al.</i>	2011	48	7.8±5.9 (small); 8.5±4.4 (large)	5 (10.4)	14 (29.2)	14 (29.2)	1 (2.1)	14.0 (small) 29.0 (large)
<i>Hocquelet et al.</i>	2014	19	Vol. 136±174 ml	2 (10.5)	2 (10.5)	2 (10.5)	0	28.0 (median)
<i>Duan et al.</i>	2015	25	12.42±5.48 (23 patients)	2 (8)	1 (4)	0	2 (8)	50.2
<b>Current series</b>	<b>2016</b>	<b>23</b>	<b>8.9 (range 2.8-24.9)</b>	<b>3 (13)</b>	<b>3 (13)</b>	<b>4 (17)</b>	<b>1 (4)</b>	<b>20.5</b>

\* Except post-embolization syndrome; NA, not available; TSC, tuberous sclerosis complex; Vol., volume

## Figures

**Figure 1.** Flow chart of the study cohort.






Figure 2




a

b




c


d



*e*



*f*



*g*




*h*



*i*

**Figure 2.** A 63 year-old woman with TSC, hospitalized for left acute flank pain, hematuria and deglobulisation. Unenhanced CT scan revealed three right AMLs (arrows) and left perirenal hematoma whose origin was a giant left AML (arrowhead), with almost no recognizable renal tissue (**a, b**). Embolization to stop bleeding was performed urgently. Selective injection of four branches of the left renal artery showed diffuse perirenal hypervascularization with neovascularization and small vascular malformations (example of left lower branch presented) (**c, d**). Angiogram after selective embolization with microspheres (Embozene<sup>®</sup>400  $\mu$ m) showed good devascularization of the lower contingent (circle outlined). The persistent hypervascular contingents (arrowheads) were treated in a second time (**e, f**). The three right AMLs were also treated in the same time with glue and microcoils. Four years after, CT-scan follow-up showed a total decreased in size of 11% of the three right AMLs with consistent viable renal parenchyma and no decrease of renal function. An average shrinkage of 17% of the left AML was also noted, without persistent perirenal collection (**g-i**).

Figure 3



*a*

*b*




*c*

*d*




*e*



*f*


*g*

*h*




*i*

*j*



**Figure 3.** A 45 year-old woman with two small incidentally discovered angiomyolipomas in the right kidney. Biopsy of the first one in the medial pole confirmed an epithelioid variant without macroscopic fat component as shown in density histogram of unenhanced CT scan after tumors segmentation (**a, b**) and the second one in the lower pole had predominant angiomyomatous content with less than 5% of fat (**c-e**). An endovascular approach was decided. Right renal angiogram demonstrates middle and inferior pole AMLs (circle outlines) (**f**). After selective embolization of the first AML with Onyx<sup>®</sup> (**g, h**) and the second one with a mixture of Glubran<sup>®</sup>2 and Lipiodol (1:6) (**i**), post-procedure angiogram showed total devascularization of both tumors (**j**). Contrast-enhanced CT scan 8 months after embolization showed total atrophy of lower pole AML (**k, l**). Maximum diameter of epithelioid middle pole AML decreased by 21% and additional percutaneous thermal ablation with microwaves was decided because of its uncertain evolution.

Figure 4



a


b

c



d

e



**Figure 4.** A 77 year-old woman hospitalized for right acute flank pain, hematuria and deglobulisation. Unenhanced CT scan revealed right perirenal hematoma caused by a giant right lower pole AML (arrows) **(a)**. Post-treatment MIP (Maximum Intensity Projection) **(b)** and VR (Volume Rendering) **(c)** images of arterial phase CT scan revealed several clusters of aneurysms on the periphery of the mass. Embolization to stop bleeding was performed urgently. Selective injection of a lower branch of the right renal artery showed hypervascularization of AML with neovascularization and aneurysms (arrows) **(d)** After selective embolization of AML with a mixture of 1:7 glue and Lipiodol **(e, f)**, post-procedure angiogram showed total exclusion of AML with good preservation of viable renal parenchyma (circle outlined) **(g)**.



**TITRE DE LA THESE :**

**TRAITEMENT DES ANGIOMYOLIPOMES RENAUX PAR EMBOLISATION ARTERIELLE SELECTIVE: UNE ETUDE RETROSPECTIVE DE 23 CAS.**

**AUTEUR :**

**BARDIN FLORIAN**

**RESUME :**

**Introduction:**

L'angiomyolipome est la tumeur rénale bénigne la plus fréquente. Son traitement s'envisage chez les patients symptomatiques ou à risque hémorragique. Les objectifs de notre étude étaient de présenter notre expérience avec le traitement des angiomyolipomes rénaux par embolisation artérielle sélective.

**Matériel et méthode:**

Dans cette étude rétrospective monocentrique, toutes les imageries, dossiers médicaux et examens de suivi des patients embolisés au cours des 11 dernières années étaient examinés. Les données démographiques et cliniques étaient recueillies et chaque tumeur embolisée était mesurée avant puis après traitement; des anévrismes intralésionnels étaient également recherchés.

**Résultats:**

Un traitement par embolisation en urgence pour hémorragie intratumorale ou en prophylaxie a été effectué chez 23 patients. Une sclérose tubéreuse de Bourneville a été confirmée chez 6 patients. Des complications majeures ont affecté 3 patients et 3 patients ont présenté une récurrence. Le taux de succès technique était de 96%. La réduction tumorale moyenne après traitement était de 26,2% et les cas sporadiques présentaient une diminution plus importante ( $p = 0,022$ ). Les anévrismes étaient plus fréquents chez les sujets hémorragiques ( $p = 0,008$ ).

**Conclusion:**

L'embolisation artérielle sélective est une thérapeutique préventive ou d'urgence efficace des angiomyolipomes rénaux avec un faible taux de récurrence ou de complication. Une approche pluridisciplinaire demeure fondamentale particulièrement pour les patients atteints de sclérose tubéreuse de Bourneville. En complément de la taille, la composition tumorale notamment anévrismale doit être prise en compte.

**MOTS-CLES : ANGIOMYOLIPOME, REIN, EMBOLISATION, SCLEROSE TUBEREUSE DE BOURNEVILLE, ARTERIOGRAPHIE, ANEVRISEME, HEMORRAGIE**